Migraine disorders are among themost common disorders of the nervous system, it has been almost seen in adultpopulation. Furthermore, North America holds the largest share in the MigraineDrug Market as it holds a large number of ageing population, according tothe U.S. Census Bureau in 2013 the aging population was around 14.1%As perWorld Health Organization (WHO) in 2016, globally it has been estimated that50% of migraine disorders was found and percentage of this disorders is foundhigh in women due to the hormonal influences. Also, according to the NationalHeadache Foundation (NHF), people from the U.S. spend more than US$ 4 billionannually on drugs in the treatment of migraine pain. The factors influencingfor migraine drugs market include increase in awareness about migrainetreatment drugs and advancement in technology in the development of migrainedrugs.
Migraine is a neurologicaldisorder that causes severe pain in head and results in nausea, vomiting, andextreme sensitivity to light and sound. The common types of migraine are withaura and without aura that means classical migraines and common migraines.Women are more prone to this disease than men. Therapeutic agents such asanti-inflammatory drugs (NSAIDs), for example aspirin, ibuprofen, sumatriptan,zolmitriptan, naproxen, anti sickness medicines and many more drugs are used tocure or lower the migraine. The symptoms of migraine can begin in childhood orin adulthood and it may progress through four stages such as prodrome, aura,headache and postdrome. Whereas aura occurs before or during a migraine, it isa symptom of nervous system that usually leads to visual disturbance such asflashes of light or zigzag vision. In this visual disturbance, around 20 to 60minutes of vision loss occurs, also the pins, needles sensation in arms can befelt. Furthermore, it may lead to difficulty in speaking and can cause for uncontrollablemovements of body.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/575
The factors that triggermigraines include hormonal changes in female body, salty food and processedfood, alcohol drinks, medications such as oral contraceptive and vasodilatorsfor example nitroglycerin can cause migraines. Latest technology such as a new,smartphone controlled wireless patch has been devised that uses electricalstimulation to reduce the pain of migraines is going to be a revolutionary formigraine patients,
Emerging drugs expected to boostthe growth of migraine drugs market in the near future
The launch of new drugs in marketis expected to boost the margarine drugs market in the forecast period. Forexample, the Indian pharmaceutical company Cadila Healthcare Ltd. (ZydusCadila) received the final approval on June 20, 2017, from the Food and DrugAdministration (FDA) to market Eletriptan Hydrobromide tablets (20 mg and 40mg), which is used in the treatment of migraine.
Furthermore, another Indianpharmaceutical company Novartis has filed its migraine drug erenumab with theEuropean Medicines Agency (EMA) on June 21, 2017. Which is expected to putother pharmaceutical companies into racing to develop a new drug for thetreatment of migraine.
Teva Pharmaceuticals IndustriesLtd. an Israeli multinational pharmaceutical company which expected to fileapproval for fremanezumab (TEV-48125) drug by Food and Drug Administration(FDA) later this year (2017). This drug will be used in chronic migraine andthe episodic migraine treatment, and this drug is expected to commercialize inmarket by the second half of 2018.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/migraine-drugs-market-575
According to the MigraineResearch Foundation (MRF), migraine is a common neurological disease, around 38million population including men, women and children in the U.S and 1 billionpopulation around the globe is affected by it as of 2017. Excessive consumptionof alcohol and increase in consumption of oral contraceptives significantlyincreases number of migraine disorder cases.
Migraine Drugs Market Key PlayersIncludes:
The increased focus on drugdevelopment expected to support the market expansion of migraine drugs marketplayers. There are various players across the globe running into thecompetition includes Endo International plc, Pfizer Inc., Aegis Therapeutics,LLC., Aeriel BioPharma, Alder BioPharmaceuticals Inc., Amgen Inc., AstellasPharma Inc., CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd.,IntelGenx Corp., Johnson & Johnson, Kowa Pharmaceuticals America, LuitpoldPharmaceuticals, Teva Pharmaceutical Industries LTD., Valeant Pharmaceuticals International,Inc., WINSTON PHARMACEUTICALS, Inc., Zogenix Inc., Abbott Laboratories,AstraZeneca plc, and GlaxoSmithKline plc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/575
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
